Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Large Cap
Health Score : 7.84Sun Pharmaceutical Industries demonstrates a strong financial performance, particularly in growth, solvency and profitability. The company shows a robust ability to meet its long-term obligations with very low debt levels. The company excels in growth metrics, including revenue, operating profit, EPS, assets, and net income, indicating an expanding business. High profitability margins and returns on capital, equity, and assets further underscore the company's financial health. While liquidity is adequate, there are areas for improvement in efficiency, specifically in asset and inventory turnover. Capital expenditure is relatively high, which may impact short-term cash flow but could drive future growth. Overall, Sun Pharmaceutical exhibits a solid financial profile with growth and profitability as key strengths, balanced by the need for enhanced operational efficiency.
Health Score : 7.84Sun Pharmaceutical Industries demonstrates a strong financial performance, particularly in growth, solvency and profitability. The company shows a robust ability to meet its long-term obligations with very low debt levels. The company excels in growth metrics, including revenue, operating profit, EPS, assets, and net income, indicating an expanding business. High profitability margins and returns on capital, equity, and assets further underscore the company's financial health. While liquidity is adequate, there are areas for improvement in efficiency, specifically in asset and inventory turnover. Capital expenditure is relatively high, which may impact short-term cash flow but could drive future growth. Overall, Sun Pharmaceutical exhibits a solid financial profile with growth and profitability as key strengths, balanced by the need for enhanced operational efficiency.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
174.05
Industry Median
29.70
Large Cap Median
29.83
P/E RATIO
39.77
P/B RATIO
5.47
Industry Median
3.58
Large Cap Median
4.48
P/S RATIO
7.74
Industry Median
3.59
Large Cap Median
4.14
Others
PEG RATIO
1.04
EV/EBITDA RATIO
23.99
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹1902.4 as on Aug 23, 2026.
Growth Score : 10.00The company exhibits strong growth across all key metrics. Revenue growth, operating profit growth, EPS growth, asset growth, and net income growth all indicate that the company is expanding its business and increasing its profitability. This robust growth performance positions the company favorably for future success and demonstrates its ability to capitalize on market opportunities. Sustaining this growth will be crucial for maintaining a competitive edge in the industry.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 15.39 | 13.54 | 10.51 | 8.41 | 11.19 |
| Operating Profit Growth Rate | 21.11 | 13.57 | 11.74 | 16.1 | 17.32 |
| Earnings Per Share (EPS) Growth | 12.73 | 158.94 | 13 | 14.13 | 5.03 |
| Asset Growth Rate | 3.19 | 15.67 | 5.72 | 7.71 | 18.36 |
| Net Income Growth Rate | 49.16 | 151.2 | 12.89 | 14.1 | 4.96 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Sun Pharmaceutical Industries Ltd | 7.84 | 39.77 | Overvalued | 17731.00 | 10.93 | 11509.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Concall Report⬤4th Feb 26
Q3 FY26 Earnings Conference Call
NEUTRAL SENTIMENT
Quarterly Report⬤31st Jan 26
Quarterly Financial Results Q3 FY 2025-26
BULLISH SENTIMENT
Concall Report⬤11th Nov 25
Q2 FY26 Earnings Call Transcript
NEUTRAL SENTIMENT
No Stock News Available at This Moment.
Sun Pharmaceutical Industries Ltd. is India's largest pharmaceutical company and the fourth-largest specialty generic pharmaceutical company globally. It develops, manufactures, and markets a broad range of pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs) across therapeutic areas. With a strong presence in over 100 countries, it focuses on both branded generics and complex specialty products, primarily in India and the US.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Sun Pharmaceutical Industries Ltd's P/E ratio (TTM) is 174.05, compared to the industry median of 29.70 and large cap median of 29.83.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Sun Pharmaceutical Industries Ltd's P/B ratio is 5.47, compared to the industry median of 3.58 and large cap median of 4.48.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Sun Pharmaceutical Industries Ltd's P/S ratio is 7.74, compared to the industry median of 3.59 and large cap median of 4.14.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Sun Pharmaceutical Industries Ltd's PEG ratio is 1.04.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Sun Pharmaceutical Industries Ltd's EV/EBITDA ratio is 23.99.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Sun Pharmaceutical Industries Ltd's ROE is 13.77%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Sun Pharmaceutical Industries Ltd's ROA is 16.30%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Sun Pharmaceutical Industries Ltd's ROCE is 21%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Sun Pharmaceutical Industries Ltd's operating margin is 30.33%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Sun Pharmaceutical Industries Ltd's net margin is 19.69%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Sun Pharmaceutical Industries Ltd's current ratio is 1.96.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Sun Pharmaceutical Industries Ltd's debt-to-equity ratio is 0.01.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Sun Pharmaceutical Industries Ltd's interest coverage ratio is 45.60.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Sun Pharmaceutical Industries Ltd's DPS is ₹15.79.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Sun Pharmaceutical Industries Ltd's EPS is 5.03.
(Source line: "Ratios as of 23 Aug 2026, based on last traded price of ₹1902.40. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1983
Headquarters: Mumbai, Maharashtra
Core Offerings: Pharmaceutical formulations (generics, specialty, branded generics), Active Pharmaceutical Ingredients (APIs), Over-the-Counter (OTC) products, Contract Research and Manufacturing Services (CRAMS)
Stock Listing: NSE (SUNPHARMA), BSE (524715)
Promoter: Dilip Shanghvi / Shanghvi family
Founded in 1983 by Dilip Shanghvi with five psychiatry products. Went public in 1994, expanding into multiple therapeutic areas. Initiated international expansion with acquisition of Caraco Pharmaceutical Laboratories in 1997 and progressively increased stake in Taro Pharmaceutical Industries starting 2007. Completed the landmark acquisition of Ranbaxy Laboratories in 2014, solidifying its position as India's largest pharmaceutical company. Continues to strengthen its global presence and R&D capabilities, focusing on specialty and complex generics.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| US Formulations | ~31% | Operating Profit |
| Emerging Markets | ~19% | Operating Profit |
| Rest of World | ~10% | Operating Profit |
| API | ~9% | Operating Profit |
India Formulations: Holds a leading market share in India's chronic therapy segments like cardiology, diabetology, neurology, and gastroenterology, driven by a strong field force and branded generics.
US Formulations: Focuses on both specialty products (dermatology, ophthalmology, CNS) and generic products, addressing a significant and profitable market.
Emerging Markets & Rest of World: Offers branded generics across various therapeutic areas in over 100 countries, adapting products to local market needs.
Active Pharmaceutical Ingredients (API): Provides backward integration for its formulation business and supplies APIs to third-party manufacturers globally, ensuring quality and cost control.
Dilip Shanghvi - Managing Director; Founder of Sun Pharma, he has led its strategic growth and transformation into India's largest pharmaceutical company through organic expansion and significant acquisitions.
Taro Pharmaceutical Industries Ltd. (a publicly listed subsidiary focused on dermatology and other specialty products, primarily in the US and Canada)
Sun Pharmaceutical Industries Inc. (US-based subsidiary for generic and specialty product sales)
Sun Pharma Laboratories Ltd. (India-based subsidiary focusing on specific formulations)
Sun Pharma Global FZE (Dubai-based entity for international operations and holdings)
Major acquisitions include Ranbaxy Laboratories in 2014 and increasing control over Taro Pharmaceutical Industries starting 2007. No significant recent bonus or rights issues reported.
The Sun Pharmaceutical Industries Ltd share price today is ₹1902.40 on NSE (SUNPHARMA), as of 24 Aug 2026.
As of 23 Aug 2026, Sun Pharmaceutical Industries Ltd share price is ₹1902.40, with previous close ₹N/A. Today's range is ₹N/A to ₹N/A. The 52-week range is ₹N/A to ₹N/A.
As of today, Sun Pharmaceutical Industries Ltd's market cap is ₹4,52,352.67 crore (Large Cap).
Sun Pharmaceutical Industries Ltd's current P/E ratio is 174.05, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 36.50.
Sun Pharmaceutical Industries Ltd's current P/B ratio is 5.47.
Sun Pharmaceutical Industries Ltd's current dividend yield is 0.83%. Last dividend of ₹5.00 per share was declared on 29-Jan-2024.
Sun Pharmaceutical Industries Ltd's EPS (TTM) is ₹5.03.
Sun Pharmaceutical Industries Ltd. is India's largest pharmaceutical company and the fourth-largest specialty generic pharmaceutical company globally. It develops, manufactures, and markets a broad range of pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs) across therapeutic areas. With a strong presence in over 100 countries, it focuses on both branded generics and complex specialty products, primarily in India and the US.
Sun Pharmaceutical Industries Ltd is promoted by Dilip Shanghvi / Shanghvi family, holding 54.48% as of 23 Aug 2026.
Sun Pharmaceutical Industries Ltd is listed on NSE (SUNPHARMA) and BSE (524715). Its next quarterly results are expected on July/August 2024.
Current Ratio